HUMAW
NASDAQ
$0.05
Humacyte Inc - Warrants (27/08/2026) (HUMAW)
Humacyte Inc. is an innovative biotechnology firm dedicated to developing and commercializing universally implantable human tissues, with a particular emphasis on its groundbreaking human acellular vessel (HAV) technology. The company is at the forefront of transforming vascular and regenerative medicine, leveraging its advanced manufacturing capabilities and robust clinical trial progress to address significant healthcare challenges. Humacyte's strategic focus on improving patient outcomes and its pipeline of transformative tissue-based solutions position it favorably for impactful partnerships and accelerated growth within the regenerative medicine market. By aligning with urgent medical needs, Humacyte is set to make a significant contribution to the future of healthcare.
This company is also listed under the following ticker: HUMA.
Website: https://www.humacyte.comBeta (5Y)
2.80
Price Chart
Profitability
Total Revenue (TTM)$1.57M
EBITDA-$97M
Operating Margin-3239%
EPS-$3.16
Growth & Risk
Beta (5Y)2.80
Sharpe Ratio-0.30